Research Solutions Inc
F:61I
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Research Solutions Inc
F:61I
|
US |
|
D
|
Dermapharm Holding SE
DUS:DMP
|
DE |
|
K
|
Kilroy Realty Corp
F:KRC
|
US |
|
D
|
Dermapharm Holding SE
XHAM:DMP
|
DE |
|
Embotelladora Andina SA
F:AKOB
|
CL |
|
U
|
Uniper SE
SWB:UN0
|
DE |
Wall St Price Targets
61I Price Targets Summary
Research Solutions Inc
According to Wall Street analysts, the average 1-year price target for 61I is 5.35 EUR with a low forecast of 5.3 EUR and a high forecast of 5.51 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 61I's stock price target?
Price Target
5.35
EUR
According to Wall Street analysts, the average 1-year price target for 61I is 5.35 EUR with a low forecast of 5.3 EUR and a high forecast of 5.51 EUR.
What is the Revenue forecast for Research Solutions Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 2%.
What is the Operating Income forecast for Research Solutions Inc?
Projected CAGR
24%
The compound annual growth rate for Operating Income over the next 3 years is 24%.
What is the Net Income forecast for Research Solutions Inc?
Projected CAGR
56%
The compound annual growth rate for Net Income over the next 3 years is 56%.
